Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
53.66 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Rhythm Pharmaceuticals, Inc. |
Symbool | RYTM |
Munteenheid | USD |
Prijs | 53.66 |
Beurswaarde | 3,297,787,986 |
Dividendpercentage | 0% |
52-weken bereik | 35.17 - 68.58 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David P. Meeker M.D. |
Website | https://www.rhythmtx.com |
An error occurred while fetching data.
Over Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)